Evaluation of systemic and mucosal anti-HPV16 and anti-HPV18 antibody responses from vaccinated women.
about
Glucopyranosyl Lipid Adjuvant (GLA), a Synthetic TLR4 agonist, promotes potent systemic and mucosal responses to intranasal immunization with HIVgp140.Immunogenicity assessment of HPV16/18 vaccine using the glutathione S-transferase L1 multiplex serology assay.Seroprevalence of 8 oncogenic human papillomavirus genotypes and acquired immunity against reinfectionCharacterization of the HPV-specific memory B cell and systemic antibody responses in women receiving an unadjuvanted HPV16 L1 VLP vaccineEpidemiological study of anti-HPV16/18 seropositivity and subsequent risk of HPV16 and -18 infections.Pre-clinical immunogenicity of human papillomavirus alpha-7 and alpha-9 major capsid proteinsIncreased plasma levels of adipokines and inflammatory markers in older women with persistent HPV infection.HPV16/18 L1 VLP vaccine induces cross-neutralizing antibodies that may mediate cross-protection.A randomized, observer-blinded immunogenicity trial of Cervarix(®) and Gardasil(®) Human Papillomavirus vaccines in 12-15 year old girls.Human papillomavirus 16 (HPV 16) and HPV 18 antibody responses measured by pseudovirus neutralization and competitive Luminex assays in a two- versus three-dose HPV vaccine trial.Developing vaccines against minor capsid antigen L2 to prevent papillomavirus infection.A competitive serological assay shows naturally acquired immunity to human papillomavirus infections in the Guanacaste Natural History Study.Glutathione S-transferase L1 multiplex serology as a measure of cumulative infection with human papillomavirusDetecting cancers through tumor-activatable minicircles that lead to a detectable blood biomarker.Secreted blood reporters: insights and applications.A murine genital-challenge model is a sensitive measure of protective antibodies against human papillomavirus infection.Relationship between Humoral Immune Responses against HPV16, HPV18, HPV31 and HPV45 in 12-15 Year Old Girls Receiving Cervarix® or Gardasil® VaccineA comparative study of two different assay kits for the detection of secreted alkaline phosphatase in HPV antibody neutralization assays.Therapeutic cancer vaccines: current status and moving forward.Neutralization of non-vaccine human papillomavirus pseudoviruses from the A7 and A9 species groups by bivalent HPV vaccine sera.Oral Immunoglobulin Levels are Not a Good Surrogate for Cervical Immunoglobulin LevelsDevelopment of a simple and quick immunochromatography method for detection of anti-HPV-16/-18 antibodies.Immunogenicity testing in human papillomavirus virus-like-particle vaccine trials.Kinetic and HPV infection effects on cross-type neutralizing antibody and avidity responses induced by Cervarix(®)Human papillomavirus vaccination induces neutralising antibodies in oral mucosal fluidsHuman papillomavirus infection in the oral cavity of HIV patients is not reduced by initiating antiretroviral therapy.Differences in the concentration and correlation of cervical immune markers among HPV positive and negative perimenopausal womenDetection of systemic and mucosal HPV-specific IgG and IgA antibodies in adolescent girls one and two years after HPV vaccination.Determinants and correlation of systemic and cervical concentrations of total IgA and IgG.Comparison of antibody responses to human papillomavirus vaccination as measured by three assays.Cross-neutralizing antibodies elicited by the Cervarix® human papillomavirus vaccine display a range of Alpha-9 inter-type specificities.Cross-protective vaccine efficacy of the bivalent HPV vaccine against HPV31 is associated with humoral immune responses: results from the Costa Rica Vaccine Trial.HPV disease transmission protection and control.Assessment of mucosal immunity to HIV-1.Recent clinical experience with vaccines using MPL- and QS-21-containing adjuvant systems.Functional assessment and structural basis of antibody binding to human papillomavirus capsid.The prevalence of HPV infections in HPV-vaccinated women from the general population.Therapeutic Cancer Vaccines.Immunogenicity of HPV prophylactic vaccines: Serology assays and their use in HPV vaccine evaluation and development.
P2860
Q31076192-9A612DCD-9BE8-4CB1-98B8-3A0DEFC51149Q33723312-0CC6941D-DC28-47E9-ACAD-79AEEDFEB555Q33947813-4BDB84EF-8753-4DD2-88DF-3E2887936763Q34032367-7B347ED3-1FA0-491E-8B53-F51D60B35877Q34267472-9D24E1AD-3786-4E04-ACC9-7A7ADAEDE37EQ34492140-E070C214-D75B-4BCD-83EE-C7DD6230B2F5Q34553461-E567BBC4-8910-43FC-9B0F-C0FC05D60E0DQ34612818-9E226219-774B-4CE9-93EF-D45DFA6CE3A6Q34708325-722048B9-96BD-4110-86E1-747335BE8E7CQ34738944-0D1271B3-3EC6-4DB5-85B8-F36CC13F7E38Q34786808-D4687A92-F6C1-4CAB-BBE2-704A2ADADC91Q35088658-F77AE952-06EA-429C-8C4B-392BADA7C3FDQ35109451-E825DEC3-A71E-4B9E-A085-BED7406AB86CQ35190027-61E9C0CC-8A20-4A4F-9669-0B1590DB4016Q35294368-9383D043-8ECB-4A77-BD8D-D2B601D7C09EQ35599310-8756C242-5D82-4A2F-BE6F-C48071FEA9DBQ35818648-5153A7A6-7A68-4124-BA6F-6C1660FF2FB6Q35887709-0F51D946-66E2-4054-AA63-43FF09EE2F16Q35894347-66FA17A7-723B-46D4-8194-069F1F016086Q35985515-109E74A4-686E-47BC-B4DD-6744D68269F5Q36054504-63CA2F17-A95F-4DF6-881C-42BA7DDBCB4DQ36269739-216A313F-1994-45D8-A0E4-A12AED8CAAE8Q36305499-B52DF776-AAF0-4B2C-842A-C3D5F20CC999Q36480943-1B2A2D77-5012-4CC1-AB46-F8F8D74DEF7CQ36750553-0BFE1076-019B-46EC-8185-1F68E5269D00Q36988090-04A7B637-DE0D-446A-9ED5-98170C21AE02Q37318334-5C0C10BB-970C-4DD9-ACCA-845588C2C8B4Q37384735-C5C54DF4-001F-4651-91B0-2A331FBB7E0AQ37388424-A10AFF4B-DA88-43CE-B4F7-34A7C7F50149Q37466826-5D7586BA-9284-436E-BC74-BE55EF1D95E4Q37671423-D4609F04-7FBE-4BAD-BFE3-7D9070F19F23Q37683122-2B8A71CB-5A32-4983-9F0B-573572DA6551Q37705703-0A346F35-8B20-4835-A546-D6A12572A131Q37724856-A8299D02-FE84-4F09-8A9F-C3F8A8785016Q37867102-2CA8A528-1E20-407A-AF05-DFF2415A916AQ38671633-5EBA4962-E22F-4678-9923-EAA1F9950371Q40291505-2648A071-831D-4225-BDB6-3EF13B3A35EEQ40728648-46F17AA2-07C9-4D50-B727-A10AF101DBFBQ47549756-50DE1A6B-4780-47FB-A67E-0B8B664ED29D
P2860
Evaluation of systemic and mucosal anti-HPV16 and anti-HPV18 antibody responses from vaccinated women.
description
2008 nî lūn-bûn
@nan
2008 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Evaluation of systemic and muc ...... sponses from vaccinated women.
@ast
Evaluation of systemic and muc ...... sponses from vaccinated women.
@en
Evaluation of systemic and muc ...... sponses from vaccinated women.
@nl
type
label
Evaluation of systemic and muc ...... sponses from vaccinated women.
@ast
Evaluation of systemic and muc ...... sponses from vaccinated women.
@en
Evaluation of systemic and muc ...... sponses from vaccinated women.
@nl
prefLabel
Evaluation of systemic and muc ...... sponses from vaccinated women.
@ast
Evaluation of systemic and muc ...... sponses from vaccinated women.
@en
Evaluation of systemic and muc ...... sponses from vaccinated women.
@nl
P2093
P2860
P1433
P1476
Evaluation of systemic and muc ...... sponses from vaccinated women.
@en
P2093
Alfonso García-Piñeres
Carolina Porras
Costa Rica Vaccine Trial (CVT) Group
Francis Dessy
Ligia A Pinto
Rolando Herrero
Roni T Falk
Sandra L Giannini
Sylviane Poncelet
Troy J Kemp
P2860
P304
P356
10.1016/J.VACCINE.2008.04.074
P407
P577
2008-05-19T00:00:00Z